The Secondary Prevention of Small Subcortical Strokes (SPS3) study

Background Small subcortical strokes, also known as lacunar strokes, comprise more than 25% of brain infarcts, and the underlying vasculopathy is the most common cause of vascular cognitive impairment. How to optimally prevent stroke recurrence and cognitive decline in S3 patients is unclear. The ai...

Full description

Saved in:
Bibliographic Details
Published in:International journal of stroke 2011-04, Vol.6 (2), p.164-175
Main Authors: Benavente, Oscar R., White, Carole L., Pearce, Lesly, Pergola, Pablo, Roldan, Ana, Benavente, Marie-France, Coffey, Christopher, McClure, Leslie A., Szychowski, Jeff M., Conwit, Robin, Heberling, Patricia A., Howard, George, Bazan, Carlos, Vidal-Pergola, Gabriela, Talbert, Robert, Hart, Robert G.
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
antiplatelet therapy
Aspirin
Aspirin - therapeutic use
Blood pressure
Brain
Clinical trials
Clopidogrel
Cognition Disorders - etiology
Cognition Disorders - prevention & control
Cognitive ability
Humans
hypertension
Hypertension - prevention & control
lacunar stroke
Magnetic Resonance Imaging
Platelet Aggregation Inhibitors - therapeutic use
randomised clinical trial
Research Design
Secondary Prevention - methods
SPS3
Stroke
Stroke - complications
Stroke - prevention & control
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Vascular diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Small subcortical strokes, also known as lacunar strokes, comprise more than 25% of brain infarcts, and the underlying vasculopathy is the most common cause of vascular cognitive impairment. How to optimally prevent stroke recurrence and cognitive decline in S3 patients is unclear. The aim of the Secondary Prevention of Small Subcortical Strokes study (Trial registration: NCT00059306) is to define strategies for reducing stroke recurrence, cognitive decline, and major vascular events. Methods Secondary Prevention of Small Subcortical Strokes is a randomised, multicentre clinical trial (n=3000) being conducted in seven countries, and sponsored by the US NINDS/NIH. Patients with symptomatic small subcortical strokes in the six-months before and an eligible lesion on magnetic resonance imaging are simultaneously randomised, in a 2 × 2 factorial design, to antiplatelet therapy – 325 mg aspirin daily plus 75 mg clopidogrel daily, vs. 325 mg aspirin daily plus placebo, double-blind – and to one of two levels of systolic blood pressure targets –‘intensive’ (
ISSN:1747-4930
1747-4949
DOI:10.1111/j.1747-4949.2010.00573.x